Eli Lilly & Co. — Medicare Part D spending
Rank #3 by attributed Part D spend · 54 tracked drugs · CMS data year 2023
About $15,906,450,951 of Medicare Part D spending in 2023 is attributed to Eli Lilly & Co. across the 54 of its drugs tracked here, ranking it #3 among manufacturers on this site. Its biggest Part D drug is Trulicity at $7,363,856,224. Attribution uses the CMS manufacturer lists and is indicative, not definitive. These are aggregate program figures, not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Eli Lilly & Co. drugs in Medicare Part D (2023)
| Brand | Generic | Total spend | Per dosage unit | Beneficiaries | Spend rank |
|---|---|---|---|---|---|
| <a href="/drug/trulicity-dulaglutide/">Trulicity</a> | Dulaglutide | $7,363,856,224 | $483.21 | 938,731 | #4 |
| <a href="/drug/mounjaro-tirzepatide/">Mounjaro</a> | Tirzepatide | $2,361,384,157 | $539.82 | 370,203 | #18 |
| <a href="/drug/humalog-kwikpen-u-100-insulin-lispro/">Humalog Kwikpen U-100</a> | Insulin Lispro | $1,208,385,334 | $35.80 | 418,431 | #40 |
| <a href="/drug/verzenio-abemaciclib/">Verzenio</a> | Abemaciclib | $756,850,867 | $275.07 | 8,217 | #71 |
| <a href="/drug/basaglar-kwikpen-u-100-insulin-glargine-hum-rec-anlog/">Basaglar Kwikpen U-100</a> | Insulin Glargine,Hum.Rec.Anlog | $647,548,319 | $23.18 | 352,073 | #82 |
| <a href="/drug/taltz-autoinjector-ixekizumab/">Taltz Autoinjector</a> | Ixekizumab | $474,538,369 | $6,885.05 | 8,491 | #112 |
| <a href="/drug/humalog-insulin-lispro/">Humalog</a> | Insulin Lispro | $458,058,582 | $26.87 | 156,031 | #117 |
| <a href="/drug/forteo-teriparatide/">Forteo</a> | Teriparatide | $425,012,975 | $1,735.90 | 15,602 | #127 |
| <a href="/drug/humulin-r-u-500-kwikpen-insulin-regular-human/">Humulin R U-500 Kwikpen</a> | Insulin Regular, Human | $263,635,305 | $97.23 | 26,073 | #184 |
| <a href="/drug/emgality-pen-galcanezumab-gnlm/">Emgality Pen</a> | Galcanezumab-Gnlm | $229,252,597 | $716.06 | 46,469 | #202 |
| <a href="/drug/humalog-kwikpen-u-200-insulin-lispro/">Humalog Kwikpen U-200</a> | Insulin Lispro | $224,440,404 | $73.76 | 40,611 | #205 |
| <a href="/drug/humalog-mix-75-25-kwikpen-insulin-lispro-protamin-lispro/">Humalog Mix 75-25 Kwikpen</a> | Insulin Lispro Protamin/Lispro | $213,875,690 | $36.40 | 40,527 | #210 |
| <a href="/drug/insulin-lispro-kwikpen-u-100-insulin-lispro/">Insulin Lispro Kwikpen U-100</a> | Insulin Lispro | $129,467,811 | $11.34 | 215,312 | #326 |
| <a href="/drug/humulin-70-30-kwikpen-insulin-nph-hum-reg-insulin-hm/">Humulin 70/30 Kwikpen</a> | Insulin NPh Hum/Reg Insulin Hm | $124,346,168 | $25.46 | 36,266 | #339 |
| Humulin 70-30 | Insulin NPh Hum/Reg Insulin Hm | $117,022,878 | $13.09 | 53,022 | #352 |
| Humulin N | Insulin NPh Human Isophane | $94,070,976 | $7.47 | 87,919 | #411 |
| Humulin R U-500 | Insulin Regular, Human | $70,632,911 | $76.89 | 6,155 | #506 |
| Humulin N Kwikpen | Insulin NPh Human Isophane | $67,544,069 | $15.40 | 45,050 | #519 |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | $59,917,382 | $29.51 | 12,749 | #561 |
| Taltz Autoinjector (2 Pack) | Ixekizumab | $59,232,799 | $6,922.15 | 2,151 | #567 |
| Retevmo | Selpercatinib | $57,651,230 | $167.30 | 479 | #572 |
| Humulin R | Insulin Regular, Human | $52,271,366 | $9.67 | 63,654 | #604 |
| Jaypirca | Pirtobrutinib | $49,251,883 | $369.96 | 647 | #623 |
| Emgality Syringe | Galcanezumab-Gnlm | $42,619,979 | $696.39 | 9,544 | #659 |
| Taltz Syringe | Ixekizumab | $41,798,563 | $6,895.18 | 730 | #667 |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | $37,737,192 | $37.12 | 13,588 | #702 |
| Taltz Autoinjector (3 Pack) | Ixekizumab | $30,764,995 | $6,905.72 | 1,258 | #779 |
| Adcirca | Tadalafil | $29,259,353 | $71.55 | 802 | #802 |
| Olumiant | Baricitinib | $28,345,232 | $101.66 | 1,389 | #814 |
| Baqsimi | Glucagon | $25,476,037 | $295.57 | 32,681 | #863 |
| Insulin Lispro | Insulin Lispro | $22,146,361 | $4.77 | 73,705 | #924 |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | $20,294,452 | $36.46 | 3,890 | #952 |
| Cymbalta | Duloxetine HCl | $18,144,205 | $9.57 | 4,693 | #996 |
| Lyumjev | Insulin Lispro-Aabc | $14,719,969 | $28.78 | 3,723 | #1079 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | $13,610,450 | $11.25 | 12,095 | #1111 |
| Reyvow | Lasmiditan Succinate | $9,927,259 | $97.78 | 3,027 | #1227 |
| Humalog Junior Kwikpen | Insulin Lispro | $9,905,950 | $35.53 | 5,648 | #1231 |
| Lyumjev Kwikpen U-200 | Insulin Lispro-Aabc | $9,887,087 | $74.61 | 1,745 | #1232 |
| Erbitux | Cetuximab | $6,921,103 | $15.98 | 110 | #1380 |
| Humatrope | Somatropin | $6,210,736 | $1,499.13 | 313 | #1419 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Frequently asked questions
How much Medicare Part D spending does Eli Lilly & Co. get?
In 2023, about $15,906,450,951 of Medicare Part D spending is attributed to Eli Lilly & Co. across the 54 of its drugs tracked here. Its biggest is Trulicity at $7,363,856,224. This is gross program spending, not what patients pay. Source: CMS, data year 2023.
What is Eli Lilly & Co.'s top Medicare Part D drug?
Among the drugs tracked here, Eli Lilly & Co.'s highest Part D spending in 2023 is Trulicity at $7,363,856,224 (national rank #4 by total spend).
Is manufacturer attribution exact?
No. CMS may list multiple manufacturers per drug, and labeler relationships change over time. We attribute each drug to its primary listed manufacturer, so these rollups are indicative rather than definitive. Always check the underlying CMS file for a specific drug.
Keep exploring
Data: CMS Medicare Part D Spending by Drug (data year 2023), U.S. public domain. Aggregate program spending, not prices. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-21